INTELLIGENT BIO SOLUTIONS INC.
INTELLIGENT BIO SOLUTIONS INC. Q2 FY2022 earnings call
February 10, 2022 · fiscal period ended 2021-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2022-02-10
Management highlights
Clinical Advancements
- In December, licensee LSBD filed for FDA breakthrough device designation for saliva glucose biosensor, but needed further data generation.
- Submitted clinical trial protocol to Mills Peninsula Medical Center in California for a 40-subject study to explore salivary vs. plasma glucose relationship, expected to complete by July 2022.
Manufacturing Advancements
- Received $4.7M Australian government grant for biosensor manufacturing facility, sourcing equipment starting in April 2022.
- Discussing with University of Newcastle for location, build-out, and commissioning of the facility.
- Evaluating expressions of interest for further Australian government funding under medical research commercialization initiative.
Guidance
Cash Runway
- As of Dec 31, 2021, cash, cash equivalents, and marketable securities totaled ~$11.19M, sufficient to cover expenses and capital requirements into the first half of 2023.
Risks
Risks
- Forward-looking statements involve risks like developing/commercializing diagnostics, partnerships, regulatory approvals. Known and unknown risks in public filings with SEC.
Q&A highlights
Q: Any progress on partner identification for Chinese markets?
A: Short list discussions are commencing, not yet conclusive.
Q: Update on COVID progress with Wyss Institute?
A: Progress is excellent, expecting further announcements within the next quarter, but no current update.
Q: Glucose sensor trial timeline and next steps?
A: Study expected to complete in July 2022, results will lead to further submissions to FDA.
Q: Update on pre-submission package to FDA?
A: Waiting for FDA response, no further progress yet as FDA was busy with COVID.
Q: Partnership with University of Newcastle for manufacturing facility?
A: Sourcing equipment to be installed on Newcastle's premises to expedite commercialization and development.
Q: Timing of development and regulatory expenses?
A: Expenditure is clumpy based on milestones, difficult to average, will update as R&D milestones are delivered.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-4.60 | $-3.20 | -43.7% | — |
| Revenue | $177,791 | $300,000 | -40.7% | — |
Transcript
February 10, 2022Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.